Implantable Continuous Glucose Monitors (I-CGM)

Medicare covers implantable continuous glucose monitors (I-CGM) for beneficiaries with diabetes mellitus when the practitioner documents beneficiary (or caregiver) training, the device is prescribed per FDA indications, and the beneficiary is either insulin-treated or has documented problematic hypoglycemia (recurrent level 2 events or one level 3 event). Continued coverage requires the treating practitioner to document adherence via an in-person or Medicare-approved telehealth visit every six months; I-CGMs are not covered for short-term use of 72 hours to 1 week. All claims must also satisfy applicable CMS national coverage, medical necessity, and payment rules.

"Beneficiary has a diagnosis of diabetes mellitus (type 1 or type 2)."

Sign up to see full coverage criteria, indications, and limitations.